Bugworks

Linked-in

LG – Lead Generation
LO – Lead Optimization
P1 – Phase 1
P2 – Phase 2

BWC0977

IV + Oral step down small molecule agent for treating critical care infections

LG

LO

P1

P2

GYROX NXTGEN

IV + Oral step down small molecule agent for treating critical care and community infections

LG

LO

P1

P2

Coverage:

  • Critical priority pathogens including carbapenem resistant Enterobacteriaceae, Acinetobacter baumannii & Pseudomonas aeruginosa
  • High priority pathogens including Enterococcus faecium, Staphylococcus aureus, Campylobacter sp., Streptococcus pneumoniae
  • Bio-threat pathogens including Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei

BWC2094

A triple effector of Adenosine axis

LG

LO

P1

P2

Coverage:

    • Adenosine pathway Implied in CRC, NSCLC, TNBC, PANCREAS, PROSTATE, RCC, HNSCC
    • No FDA approved small molecule drug yet
    • Available immuno-oncology drugs are biologics presenting with huge cost and toxicity liabilities
    • Has a potential for combination with approved immune checkpoint drugs, cytotoxics and targeted therapies
    • Potential for combination with cell-based therapy (CAR-T and NK-CAR, etc.)

BWC5044/BWC5077

CDK7 Inhibitors

LG

LO

P1

P2

Coverage:

  • Small molecule therapeutics for treating recalcitrant tumors

BWC5036/BWC5089

ATM/DNA-PK(DUAL) Inhibitors

LG

LO

P1

P2

Coverage:
  • Small molecule therapeutics for treating recalcitrant tumors

BWC4496

HPK1 Inhibitors

LG

LO

P1

P2

Coverage:
  • Small molecule therapeutics for treating recalcitrant tumors

Spliceosome Modulators/DNA Damage

LG

LO

P1

P2

Coverage:

    • Small molecule therapeutics for treating recalcitrant tumors
    • ADC Payload Opportunity

PTPN1/2(DUAL) Inhibitor

LG

LO

P1

P2

Coverage:
  • Small molecule therapeutics for treating recalcitrant tumors

CDK2 Inhibitor

LG

LO

P1

P2

Coverage:

  • Small molecule therapeutics for treating recalcitrant tumors

Human Topo I Inhibitor.

LG

LO

P1

P2

Coverage:

  • Small molecule therapeutics for treating recalcitrant tumors
  • Potential ADC payload

Partners

Partner-CTA
to top